Home / Intelligence / White Papers / Launching During COVID-19 Whitepaper
| What is and isn’t working for drug launches amid COVID-19? Six months after COVID-19 lock-downs began, Trinity has uncovered some surprising (and some concerning) answers to key questions everyone is asking. |
| In this paper, we examine the trajectory of new molecular entities (NMEs) approved in late 2019 and early 2020 to understand how to drive a successful drug launch (and avoid the pitfalls) in the age of COVID-19. |
We would contact you in accordance with our Privacy Policy, which we invite you to visit for details about our data privacy practices, including, where appropriate, how you may access and correct the personal data we store or withdraw consent to the collection, use or disclosure of such information. We will not share your email address or personal information. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Related Intelligence
White Papers
Predicting Winners: AI-Powered Portfolio Management
Can artificial intelligence and machine learning (AIML) be used to support portfolio decision-making across the life sciences industry? In this installment of our Industry Impact Series, we find that not only can the latest AIML techniques identify the drivers of success and failure in commercialization, but Trinity Life Sciences’ AI algorithm accurately predicts revenue outcomes for […]
Read More
Webinars
Launch & Learn: Trinity Launch Accelerator
Available On Demand
Today’s launch environment is fraught with greater complexity, lack of standardization and executional inefficiency. Join us for a virtual lunch and learn where experts share how Launch Accelerator enables teams to overcome launch barriers with a simple launch readiness and management process.
Watch Now
Webinars
Trinity Annual Drug Index
Available On Demand
White Paper & On-demand Webinar: This report, the seventh in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. We provide a comprehensive evaluation of the performance of novel drugs approved by the FDA in 2021, scoring each […]
Watch Now